In the future these properties may be exploited to inhibit oxidative phosphorylation in cancer cells which are particularly dependent on it, such as in prostate cancer [74], cancer cells with up-regulated OCT1 transporters, such in as ovarian cancer [61], or cancer cells with detrimental complex I mutations that render them hypersensitive to inhibitors [75]. Here, SLC22A1 is linked to prostate carcinoma.